


## (S)-Renzapride

<b>Cat. No.:</b>	HY-14147A		
<b>Molecular Formula:</b>	C <sub>16</sub> H <sub>22</sub> ClN <sub>3</sub> O <sub>2</sub>		
<b>Molecular Weight:</b>	323.82		
<b>Target:</b>	5-HT Receptor		
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 35 mg/mL (108.08 mM; Need ultrasonic)

Concentration	Mass			
	1 mg	5 mg	10 mg	
1 mM	3.0881 mL	15.4407 mL	30.8814 mL	
5 mM	0.6176 mL	3.0881 mL	6.1763 mL	
10 mM	0.3088 mL	1.5441 mL	3.0881 mL	

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

(S)-Renzapride ((S)-BRL 24924) is the isomer of HY-14147 Renzapride. Renzapride is a 5-HT<sub>4</sub> receptor agonist with a K<sub>i</sub> value of 115 nM. Renzapride also is a 5HT<sub>2b</sub> and 5HT<sub>3</sub> receptor antagonist. Renzapride can be used for constipation predominant irritable bowel syndrome (C-IBS) study<sup>[1][2]</sup>.

### REFERENCES

- [1]. Camilleri M, et al. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol. 2004;2(10):895-904.
- [2]. Scarpellini E, et al. Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome. Expert Opin Investig Drugs. 2008;17(11):1663-1670.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA